New Elite Feature: Screen & Chart at the same time

Werewolf Therapeutics, Inc.

Contributing Author

Recent Articles by Werewolf Therapeutics, Inc.

May-07	Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates HOWL +9.68% HOWL GlobeNewswire
Mar-27	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates HOWL -9.54% GlobeNewswire
Feb-24	Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives HOWL GlobeNewswire
Dec-18	Werewolf Therapeutics Announces Pipeline and Business Updates HOWL -39.57% GlobeNewswire
Nov-07	Werewolf Therapeutics Presents Data Expanding Its PREDATOR Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HOWL GlobeNewswire
Nov-04	Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update HOWL -7.63% GlobeNewswire
Oct-08	Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer HOWL GlobeNewswire
Oct-03	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HOWL +6.77% GlobeNewswire
Sep-02	Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference HOWL GlobeNewswire
Aug-14	Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
Jul-09	Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit HOWL GlobeNewswire
Jun-12	Werewolf Therapeutics to Participate in the BIO International Convention HOWL GlobeNewswire
May-29	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference HOWL GlobeNewswire
May-20	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 HOWL -5.26% HOWL GlobeNewswire
May-13	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit HOWL GlobeNewswire
May-08	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update HOWL -5.54% GlobeNewswire
May-05	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting HOWL GlobeNewswire
May-05	Werewolf Therapeutics to Participate in Upcoming Investor Conferences HOWL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)